Monopar Therapeutics Inc.

NasdaqCM:MNPR Stock Report

Market Cap: US$116.4m

Monopar Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:MNPR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
28 Oct 24BuyUS$25,188Karthik RadhakrishnanIndividual1,550US$16.25
20 Jun 24BuyUS$25,574Andrew CittadineIndividual6,501.6US$4.30
17 Jun 24BuyUS$32,894Andrew CittadineIndividual7,200US$4.66
04 Jun 24BuyUS$18,480Andrew CittadineIndividual4,800US$3.90
31 May 24BuyUS$23,051Andrew CittadineIndividual7,200US$3.22

Insider Trading Volume

Insider Buying: MNPR insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of MNPR?
Owner TypeNumber of SharesOwnership Percentage
Public Companies387,3297.34%
Individual Insiders401,9517.62%
VC/PE Firms511,2079.69%
Institutions787,22214.9%
Private Companies855,58916.2%
General Public2,334,49844.2%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 77.5%.

Top Shareholders

Top 24 shareholders own 55.77% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
16.2%
Tactic Pharma LLC
855,589US$18.9m-41.7%no data
10.7%
Janus Henderson Group plc
562,482US$12.4m0%0.01%
9.69%
RA Capital Management, L.P.
511,207US$11.3m0%0.15%
7.34%
AstraZeneca PLC
387,329US$8.5m0%no data
3.79%
Tang Capital Management, LLC
200,000US$4.4m0%0.36%
2.63%
Jeffrey Klunzinger
138,560US$3.1m0%no data
1.78%
Diane Hendricks
93,750US$2.1m0%no data
1.06%
Chandler Robinson
56,162US$1.2m0%no data
0.76%
Andrew Cittadine
39,869US$879.1k3.25%no data
0.59%
Michael Brown
31,173US$687.4k-33.9%no data
0.29%
Christopher Starr
15,053US$331.9k0%no data
0.27%
Geode Capital Management, LLC
14,066US$310.2k17.1%no data
0.22%
Kim Tsuchimoto
11,486US$253.3k0%no data
0.17%
The Vanguard Group, Inc.
9,033US$199.2k0%no data
0.12%
Arthur Klausner
6,173US$136.1k0%no data
0.1%
Raymond Anderson
5,373US$118.5k0%no data
0.053%
Thomas O'Halloran
2,801US$61.8k0%no data
0.029%
Karthik Radhakrishnan
1,550US$34.2k0%no data
0.011%
NewEdge Advisors, LLC
600US$13.2k0%no data
0.0097%
UBS Asset Management AG
512US$11.3k0%no data
0.0095%
Wells Fargo & Company, Securities and Brokerage Investments
500US$11.0k0%no data
0.0003%
Fédération des Caisses Desjardins du Québec, Asset Management Arm
16US$349.10%no data
0.00025%
Bank of America Corporation, Asset Management Arm
13US$290.9-88.4%no data
0.00002%
Andrew Mazar
1US$23.3-100%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 00:38
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Monopar Therapeutics Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian Kemp DolliverBrookline Capital Markets
Kumaraguru RajaBrookline Capital Markets
Sean LeeH.C. Wainwright & Co.